文献速递胃肠外科围术期管理与 ERAS

腹腔镜肿瘤细胞减灭术联合HIPEC围手术期结局改善:单中心倾向匹配早期经验

Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis.
PubMed 文献 · Surg Endosc · 2022-01-26

本研究比较腹腔镜与开腹肿瘤细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)在低体积腹膜病变患者中的围手术期及肿瘤学结局。2008至2017年,16例腹腔镜CRS/HIPEC与32例按PCI、细胞减灭 completeness及肿瘤组织学匹配的开腹CRS/HIPEC对照比较。腹腔镜组估计失血量更少、住院时间更短、30天并发症率更低,两组无进展生存与总生存无差异。

要点

  • 低体积腹膜病变患者中,腹腔镜CRS/HIPEC可行且安全。
  • 腹腔镜组30天并发症率6.3%,开腹组56.3%,差异有统计学意义。
  • 两组无进展生存(p=0.577)与总生存(p=0.472)无差异。

核心结论

  • 腹腔镜CRS/HIPEC在选择的低肿瘤体积患者中用于治愈性治疗是可行且安全的。
  • 微创CRS/HIPEC与更少的术后并发症和更短的住院时间相关。
  • 两组长期肿瘤学结局无差异。

研究设计与样本

  • 单中心早期经验,使用前瞻性维护数据库。
  • 16例腹腔镜CRS/HIPEC患者与32例开腹CRS/HIPEC对照按PCI、细胞减灭 completeness及肿瘤组织学匹配比较。
  • 研究时段为2008年至2017年。

主要发现

  • 腹腔镜组估计失血量中位数150 mL(IQR 50-300) vs 开腹组100 mL(IQR 50-125),p=0.04。
  • 腹腔镜组住院时间中位数4天(IQR 3-6) vs 开腹组6天(IQR 5-8),p<0.01。
  • 腹腔镜组30天并发症率6.3% vs 开腹组56.3%,p<0.01。
  • 两组无进展生存无差异(p=0.577),总生存无差异(p=0.472)。
  • 两组PCI、切除器官数量及最佳细胞减灭率相当。

关键数值与推荐

  • 腹腔镜组估计失血量中位数150 mL(IQR 50-300) vs 开腹组100 mL(IQR 50-125),p=0.04。
  • 腹腔镜组住院时间中位数4天(IQR 3-6) vs 开腹组6天(IQR 5-8),p<0.01。
  • 腹腔镜组30天并发症率6.3% vs 开腹组56.3%,p<0.01。
  • 无进展生存组间比较p=0.577,总生存组间比较p=0.472。

临床怎么用

  • 对于选择的低肿瘤体积患者,腹腔镜CRS/HIPEC可作为治愈性治疗选项。
  • 微创方式与更少术后并发症和更短住院时间相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The role of laparoscopy in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is not well established. Herein, we describe our early experience of laparoscopic CRS/HIPEC in patients with low-volume peritoneal disease compared to patients who underwent open CRS/HIPEC during the same time period. METHODS: Using a prospectively maintained database, patients who underwent laparoscopic CRS/HIPEC were compared to a control cohort of patients who underwent open CRS/HIPEC, matched for peritoneal carcinomatosis index (PCI), completeness of cytoreduction, and tumor histology. RESULTS: Between 2008 and 2017, 16 patients underwent laparoscopic CRS/HIPEC and were compared to a matched control cohort of 32 patients who underwent open CRS/HIPEC. Clinical and demographic data were similar between the groups. PCI, number of resected organs, and optimal cytoreduction rates were comparable. Patients who underwent laparoscopic experienced a lower estimated blood loss, (median, [IQR 1-3]); 150 mL, [50-300] vs. 100 mL, [50-125], p = 0.04, shorter length of stay (median [IQR 1-3]; 4 days [3-6] vs. 6 days [5-8], p < 0.01, and a lower 30-day complication rate (6.3% vs. 56.3%, p < 0.01). There was no difference in progression-free survival (p = 0.577) and overall survival (p = 0.472) between the groups. CONCLUSIONS: This preliminary study demonstrates that laparoscopic CRS/HIPEC is feasible and safe for curative treatment in selected patients with low tumor volume. Minimally invasive CRS/HIPEC is associated with fewer postoperative complications and shorter length of stay. There was no difference in long-term oncological outcomes between the groups.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Shaltiel T, Solomon D, Pletcher ER, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with improved perioperative outcomes: a single-center early experience propensity-matched analysis. Surg Endosc. 2022. PMID: 35080674. doi:10.1007/s00464-022-09034-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。